Microbially Produced Imidazole Propionate Impairs Insulin Signaling through mTORC1

Cell

Volumn 175, Issue 4, 2018, Pages 947-961.e17

  Koh, Ara ^a   Molinaro, Antonio ^a   Ståhlman, Marcus ^a   Khan, Muhammad Tanweer ^a   Schmidt, Caroline ^a,b   Mannerås Holm, Louise ^a   Wu, Hao ^a   Carreras, Alba ^a   Jeong, Heeyoon ^c   Olofsson, Louise E ^a   Bergh, Per Olof ^a   Gerdes, Victor ^d   Hartstra, Annick ^e   de Brauw, Maurits ^d   Perkins, Rosie ^a   Nieuwdorp, Max ^a,e,f   Bergström, Göran ^a,b   Bäckhed, Fredrik ^a,g  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c Pohang University of Science and Technology (POSTECH)   (South Korea)

^d SLOTERVAART HOSPITAL   (Netherlands)

^e UNIVERSITY OF AMSTERDAM   (Netherlands)

^f VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^g Capital Region   (Denmark)

Author keywords

histidine; imidazole propionate; IRS; microbiome; mTORC1; p38 ; p62

Indexed keywords

AMINO ACID DERIVATIVE; HISTIDINE; IMIDAZOLE PROPIONATE; INSULIN; INSULIN RECEPTOR SUBSTRATE; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN P38 GAMMA; SEQUESTOSOME 1; UNCLASSIFIED DRUG; 5-IMIDAZOLEPROPIONIC ACID; IMIDAZOLE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOSYNTHESIS; CONTROLLED STUDY; FECES MICROFLORA; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN SIGNALING; LIVER; MALE; METABOLITE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; ANIMAL; C57BL MOUSE; CELL CULTURE; HEK293 CELL LINE; INTESTINE FLORA; METABOLISM; MICROBIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; CELLS, CULTURED; DIABETES MELLITUS, TYPE 2; GASTROINTESTINAL MICROBIOME; HEK293 CELLS; HISTIDINE; HUMANS; IMIDAZOLES; INSULIN; LIVER; MALE; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MICE; MICE, INBRED C57BL; P38 MITOGEN-ACTIVATED PROTEIN KINASES; SEQUESTOSOME-1 PROTEIN; SIGNAL TRANSDUCTION;

EID: 85055083712     PISSN: 00928674     EISSN: 10974172     Source Type: Journal    
DOI: 10.1016/j.cell.2018.09.055     Document Type: Article

References (68)

1. Anjani, K., Lhomme, M., Sokolovska, N., Poitou, C., Aron-Wisnewsky, J., Bouillot, J.L., Lesnik, P., Bedossa, P., Kontush, A., Clement, K., et al. Circulating phospholipid profiling identifies portal contribution to NASH signature in obesity. J. Hepatol. 62 (2015), 905–912.
2. Aronov, P.A., Luo, F.J.G., Plummer, N.S., Quan, Z., Holmes, S., Hostetter, T.H., Meyer, T.W., Colonic contribution to uremic solutes. J. Am. Soc. Nephrol. 22 (2011), 1769–1776.
3. Ashwell, J.D., The many paths to p38 mitogen-activated protein kinase activation in the immune system. Nat. Rev. Immunol. 6 (2006), 532–540.
4. Beardmore, V.A., Hinton, H.J., Eftychi, C., Apostolaki, M., Armaka, M., Darragh, J., McIlrath, J., Carr, J.M., Armit, L.J., Clacher, C., et al. Generation and characterization of p38beta (MAPK11) gene-targeted mice. Mol. Cell. Biol. 25 (2005), 10454–10464.
5. Beenstock, J., Ben-Yehuda, S., Melamed, D., Admon, A., Livnah, O., Ahn, N.G., Engelberg, D., The p38β mitogen-activated protein kinase possesses an intrinsic autophosphorylation activity, generated by a short region composed of the α-G helix and MAPK insert. J. Biol. Chem. 289 (2014), 23546–23556.
6. Bender, R.A., Regulation of the histidine utilization (hut) system in bacteria. Microbiol. Mol. Biol. Rev. 76 (2012), 565–584.
7. Benjamini, Y., Hochberg, Y., Controlling the false discovery rate - a practical and powerful approach to multiple testing. J. R. Stat. Soc. Series B Stat. Methodol. 57 (1995), 289–300.
8. Blagosklonny, M.V., TOR-centric view on insulin resistance and diabetic complications: perspective for endocrinologists and gerontologists. Cell Death Dis., 4, 2013, e964.
9. Bogachev, A.V., Bertsova, Y.V., Bloch, D.A., Verkhovsky, M.I., Urocanate reductase: identification of a novel anaerobic respiratory pathway in Shewanella oneidensis MR-1. Mol. Microbiol. 86 (2012), 1452–1463.
10. Camacho, C., Coulouris, G., Avagyan, V., Ma, N., Papadopoulos, J., Bealer, K., Madden, T.L., BLAST+: architecture and applications. BMC Bioinformatics, 10, 2009, 421.
11. Chen, Q., Reimer, R.A., Dairy protein and leucine alter GLP-1 release and mRNA of genes involved in intestinal lipid metabolism in vitro. Nutrition 25 (2009), 340–349.
12. Copp, J., Manning, G., Hunter, T., TORC-specific phosphorylation of mammalian target of rapamycin (mTOR): phospho-Ser2481 is a marker for intact mTOR signaling complex 2. Cancer Res. 69 (2009), 1821–1827.
13. Cotillard, A., Kennedy, S.P., Kong, L.C., Prifti, E., Pons, N., Le Chatelier, E., Almeida, M., Quinquis, B., Levenez, F., Galleron, N., et al., ANR MicroObes consortium. Dietary intervention impact on gut microbial gene richness. Nature 500 (2013), 585–588.
14. Cuenda, A., Rousseau, S., p38 MAP-kinases pathway regulation, function and role in human diseases. Biochim. Biophys. Acta 1773 (2007), 1358–1375.
15. Dodd, D., Spitzer, M.H., Van Treuren, W., Merrill, B.D., Hryckowian, A.J., Higginbottom, S.K., Le, A., Cowan, T.M., Nolan, G.P., Fischbach, M.A., Sonnenburg, J.L., A gut bacterial pathway metabolizes aromatic amino acids into nine circulating metabolites. Nature 551 (2017), 648–652.
16. Duran, A., Amanchy, R., Linares, J.F., Joshi, J., Abu-Baker, S., Porollo, A., Hansen, M., Moscat, J., Diaz-Meco, M.T., p62 is a key regulator of nutrient sensing in the mTORC1 pathway. Mol. Cell 44 (2011), 134–146.
17. Esposito, D.L., Li, Y., Cama, A., Quon, M.J., Tyr(612) and Tyr(632) in human insulin receptor substrate-1 are important for full activation of insulin-stimulated phosphatidylinositol 3-kinase activity and translocation of GLUT4 in adipose cells. Endocrinology 142 (2001), 2833–2840.
18. Finn, R.D., Clements, J., Eddy, S.R., HMMER web server: interactive sequence similarity searching. Nucleic Acids Res., 39, 2011 W29-37.
19. Finn, R.D., Coggill, P., Eberhardt, R.Y., Eddy, S.R., Mistry, J., Mitchell, A.L., Potter, S.C., Punta, M., Qureshi, M., Sangrador-Vegas, A., et al. The Pfam protein families database: towards a more sustainable future. Nucleic Acids Res. 44:D1 (2016), D279–D285.
20. Gaba, M., Mohan, C., Development of drugs based on imidazole and benzimidazole bioactive heterocycles: recent advances and future directions. Med. Chem. Res. 25 (2016), 173–210.
21. Ge, B., Gram, H., Di Padova, F., Huang, B., New, L., Ulevitch, R.J., Luo, Y., Han, J., MAPKK-independent activation of p38alpha mediated by TAB1-dependent autophosphorylation of p38alpha. Science 295 (2002), 1291–1294.
22. González-Terán, B., Matesanz, N., Nikolic, I., Verdugo, M.A., Sreeramkumar, V., Hernández-Cosido, L., Mora, A., Crainiciuc, G., Sáiz, M.L., Bernardo, E., et al. p38γ and p38δ reprogram liver metabolism by modulating neutrophil infiltration. EMBO J. 35 (2016), 536–552.
23. Harrington, L.S., Findlay, G.M., Gray, A., Tolkacheva, T., Wigfield, S., Rebholz, H., Barnett, J., Leslie, N.R., Cheng, S., Shepherd, P.R., et al. The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J. Cell Biol. 166 (2004), 213–223.
24. Kanehisa, M., Goto, S., KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28 (2000), 27–30.
25. Karlsson, F.H., Tremaroli, V., Nookaew, I., Bergström, G., Behre, C.J., Fagerberg, B., Nielsen, J., Bäckhed, F., Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature 498 (2013), 99–103.
26. Karlsson, F.H., Nookaew, I., Nielsen, J., Metagenomic data utilization and analysis (MEDUSA) and construction of a global gut microbial gene catalogue. PLoS Comput. Biol., 10, 2014, e1003706.
27. Kikuchi, M., Ueno, M., Itoh, Y., Suda, W., Hattori, M., Uremic toxin-producing gut microbiota in rats with chronic kidney disease. Nephron 135 (2017), 51–60.
28. Kim, L., Del Rio, L., Butcher, B.A., Mogensen, T.H., Paludan, S.R., Flavell, R.A., Denkers, E.Y., p38 MAPK autophosphorylation drives macrophage IL-12 production during intracellular infection. J. Immunol. 174 (2005), 4178–4184.
29. Kim, Y.M., Stone, M., Hwang, T.H., Kim, Y.G., Dunlevy, J.R., Griffin, T.J., Kim, D.H., SH3BP4 is a negative regulator of amino acid-Rag GTPase-mTORC1 signaling. Mol. Cell 46 (2012), 833–846.
30. Koeth, R.A., Wang, Z., Levison, B.S., Buffa, J.A., Org, E., Sheehy, B.T., Britt, E.B., Fu, X., Wu, Y., Li, L., et al. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat. Med. 19 (2013), 576–585.
31. Koh, A., De Vadder, F., Kovatcheva-Datchary, P., Bäckhed, F., From dietary fiber to host physiology: short-chain fatty acids as key bacterial metabolites. Cell 165 (2016), 1332–1345.
32. Kumar, S., Stecher, G., Tamura, K., MEGA7: molecular evolutionary genetics analysis version 7.0 for bigger datasets. Mol. Biol. Evol. 33 (2016), 1870–1874.
33. Larkin, M.A., Blackshields, G., Brown, N.P., Chenna, R., McGettigan, P.A., McWilliam, H., Valentin, F., Wallace, I.M., Wilm, A., Lopez, R., et al. Clustal W and Clustal X version 2.0. Bioinformatics 23 (2007), 2947–2948.
34. Layman, D.K., Walker, D.A., Potential importance of leucine in treatment of obesity and the metabolic syndrome. J. Nutr. 136:1, Suppl (2006), 319S–323S.
35. Le Chatelier, E., Nielsen, T., Qin, J., Prifti, E., Hildebrand, F., Falony, G., Almeida, M., Arumugam, M., Batto, J.M., Kennedy, S., et al., MetaHIT consortium. Richness of human gut microbiome correlates with metabolic markers. Nature 500 (2013), 541–546.
36. Leontieva, O.V., Demidenko, Z.N., Blagosklonny, M.V., Rapamycin reverses insulin resistance (IR) in high-glucose medium without causing IR in normoglycemic medium. Cell Death Dis., 5, 2014, e1214.
37. Linares, J.F., Duran, A., Reina-Campos, M., Aza-Blanc, P., Campos, A., Moscat, J., Diaz-Meco, M.T., Amino acid activation of mTORC1 by a PB1-domain-driven kinase complex cascade. Cell Rep. 12 (2015), 1339–1352.
38. Liu, R., Hong, J., Xu, X., Feng, Q., Zhang, D., Gu, Y., Shi, J., Zhao, S., Liu, W., Wang, X., et al. Gut microbiome and serum metabolome alterations in obesity and after weight-loss intervention. Nat. Med. 23 (2017), 859–868.
39. Love, M.I., Huber, W., Anders, S., Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol., 15, 2014, 550.
40. Mishima, E., Fukuda, S., Mukawa, C., Yuri, A., Kanemitsu, Y., Matsumoto, Y., Akiyama, Y., Fukuda, N.N., Tsukamoto, H., Asaji, K., et al. Evaluation of the impact of gut microbiota on uremic solute accumulation by a CE-TOFMS-based metabolomics approach. Kidney Int. 92 (2017), 634–645.
41. Mojtahedi, M.C., Thorpe, M.P., Karampinos, D.C., Johnson, C.L., Layman, D.K., Georgiadis, J.G., Evans, E.M., The effects of a higher protein intake during energy restriction on changes in body composition and physical function in older women. J. Gerontol. A Biol. Sci. Med. Sci. 66 (2011), 1218–1225.
42. Muto, Y., Sato, S., Watanabe, A., Moriwaki, H., Suzuki, K., Kato, A., Kato, M., Nakamura, T., Higuchi, K., Nishiguchi, S., et al., Long-Term Survival Study (LOTUS) Group. Overweight and obesity increase the risk for liver cancer in patients with liver cirrhosis and long-term oral supplementation with branched-chain amino acid granules inhibits liver carcinogenesis in heavier patients with liver cirrhosis. Hepatol. Res. 35 (2006), 204–214.
43. Ozes, O.N., Akca, H., Mayo, L.D., Gustin, J.A., Maehama, T., Dixon, J.E., Donner, D.B., A phosphatidylinositol 3-kinase/Akt/mTOR pathway mediates and PTEN antagonizes tumor necrosis factor inhibition of insulin signaling through insulin receptor substrate-1. Proc. Natl. Acad. Sci. USA 98 (2001), 4640–4645.
44. Pedersen, H.K., Gudmundsdottir, V., Nielsen, H.B., Hyotylainen, T., Nielsen, T., Jensen, B.A., Forslund, K., Hildebrand, F., Prifti, E., Falony, G., et al., MetaHIT Consortium. Human gut microbes impact host serum metabolome and insulin sensitivity. Nature 535 (2016), 376–381.
45. Qin, L.Q., Xun, P., Bujnowski, D., Daviglus, M.L., Van Horn, L., Stamler, J., He, K., INTERMAP Cooperative Research Group. Higher branched-chain amino acid intake is associated with a lower prevalence of being overweight or obese in middle-aged East Asian and Western adults. J. Nutr. 141 (2011), 249–254.
46. Qin, J., Li, Y., Cai, Z., Li, S., Zhu, J., Zhang, F., Liang, S., Zhang, W., Guan, Y., Shen, D., et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature 490 (2012), 55–60.
47. Ridaura, V.K., Faith, J.J., Rey, F.E., Cheng, J., Duncan, A.E., Kau, A.L., Griffin, N.W., Lombard, V., Henrissat, B., Bain, J.R., et al. Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science, 341, 2013, 1241214.
48. Rui, L., Fisher, T.L., Thomas, J., White, M.F., Regulation of insulin/insulin-like growth factor-1 signaling by proteasome-mediated degradation of insulin receptor substrate-2. J. Biol. Chem. 276 (2001), 40362–40367.
49. Sancak, Y., Peterson, T.R., Shaul, Y.D., Lindquist, R.A., Thoreen, C.C., Bar-Peled, L., Sabatini, D.M., The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1. Science 320 (2008), 1496–1501.
50. Schröder, I., Gunsalus, R.P., Ackrell, B.A.C., Cochran, B., Cecchini, G., Identification of active site residues of Escherichia coli fumarate reductase by site-directed mutagenesis. J. Biol. Chem. 266 (1991), 13572–13579.
51. Schroeder, B.O., Bäckhed, F., Signals from the gut microbiota to distant organs in physiology and disease. Nat. Med. 22 (2016), 1079–1089.
52. Shah, O.J., Hunter, T., Turnover of the active fraction of IRS1 involves raptor-mTOR- and S6K1-dependent serine phosphorylation in cell culture models of tuberous sclerosis. Mol. Cell. Biol. 26 (2006), 6425–6434.
53. Shoaie, S., Ghaffari, P., Kovatcheva-Datchary, P., Mardinoglu, A., Sen, P., Pujos-Guillot, E., de Wouters, T., Juste, C., Rizkalla, S., Chilloux, J., et al., MICRO-Obes Consortium. Quantifying diet-induced metabolic changes of the human gut microbiome. Cell Metab. 22 (2015), 320–331.
54. Smith, M.I., Yatsunenko, T., Manary, M.J., Trehan, I., Mkakosya, R., Cheng, J., Kau, A.L., Rich, S.S., Concannon, P., Mychaleckyj, J.C., et al. Gut microbiomes of Malawian twin pairs discordant for kwashiorkor. Science 339 (2013), 548–554.
55. Soliman, G.A., Acosta-Jaquez, H.A., Dunlop, E.A., Ekim, B., Maj, N.E., Tee, A.R., Fingar, D.C., mTOR Ser-2481 autophosphorylation monitors mTORC-specific catalytic activity and clarifies rapamycin mechanism of action. J. Biol. Chem. 285 (2010), 7866–7879.
56. Sonnenburg, J.L., Bäckhed, F., Diet-microbiota interactions as moderators of human metabolism. Nature 535 (2016), 56–64.
57. Suárez-Zamorano, N., Fabbiano, S., Chevalier, C., Stojanović, O., Colin, D.J., Stevanović, A., Veyrat-Durebex, C., Tarallo, V., Rigo, D., Germain, S., et al. Microbiota depletion promotes browning of white adipose tissue and reduces obesity. Nat. Med. 21 (2015), 1497–1501.
58. Tzatsos, A., Raptor binds the SAIN (Shc and IRS-1 NPXY binding) domain of insulin receptor substrate-1 (IRS-1) and regulates the phosphorylation of IRS-1 at Ser-636/639 by mTOR. J. Biol. Chem. 284 (2009), 22525–22534.
59. van der Heiden, C., Wadman, S.K., de Bree, P.K., Wauters, E.A., Increased urinary imidazolepropionic acid, N-acetylhistamine and other imidazole compounds in patients with intestinal disorders. Clin. Chim. Acta 39 (1972), 201–214.
60. Wallner, S., Winkler, A., Riedl, S., Dully, C., Horvath, S., Gruber, K., Macheroux, P., Catalytic and structural role of a conserved active site histidine in berberine bridge enzyme. Biochemistry 51 (2012), 6139–6147.
61. Wang, X., Beugnet, A., Murakami, M., Yamanaka, S., Proud, C.G., Distinct signaling events downstream of mTOR cooperate to mediate the effects of amino acids and insulin on initiation factor 4E-binding proteins. Mol. Cell. Biol. 25 (2005), 2558–2572.
62. Wang, Z., Klipfell, E., Bennett, B.J., Koeth, R., Levison, B.S., Dugar, B., Feldstein, A.E., Britt, E.B., Fu, X., Chung, Y.M., et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 472 (2011), 57–63.
63. Windey, K., De Preter, V., Verbeke, K., Relevance of protein fermentation to gut health. Mol. Nutr. Food Res. 56 (2012), 184–196.
64. Wu, H., Esteve, E., Tremaroli, V., Khan, M.T., Caesar, R., Mannerås-Holm, L., Ståhlman, M., Olsson, L.M., Serino, M., Planas-Fèlix, M., et al. Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug. Nat. Med. 23 (2017), 850–858.
65. Yang, Q., Guan, K.L., Expanding mTOR signaling. Cell Res. 17 (2007), 666–681.
66. Zhang, Z.Y., Dixon, J.E., Active site labeling of the Yersinia protein tyrosine phosphatase: the determination of the pKa of the active site cysteine and the function of the conserved histidine 402. Biochemistry 32 (1993), 9340–9345.
67. Zhang, Y., Guo, K., LeBlanc, R.E., Loh, D., Schwartz, G.J., Yu, Y.H., Increasing dietary leucine intake reduces diet-induced obesity and improves glucose and cholesterol metabolism in mice via multimechanisms. Diabetes 56 (2007), 1647–1654.
68. Zhang, W., Sargis, R.M., Volden, P.A., Carmean, C.M., Sun, X.J., Brady, M.J., PCB 126 and other dioxin-like PCBs specifically suppress hepatic PEPCK expression via the aryl hydrocarbon receptor. PLoS ONE, 7, 2012, e37103.